AM-831
We have discovered and, in collaboration with Meiji Seika Pharma, are developing AM-831 for the treatment of schizophrenia. AM-831 is a novel and orally available small molecule that combines muscarinic m1 partial agonism with both dopamine D2 and serotonin 5-HT2A receptor antagonism. AM-831 has demonstrated robust effects in preclinical models of psychosis and pro-cognitive effects in preclinical behavioral models. Currently prescribed treatments do not effectively address or may exacerbate cognitive disturbances associated with schizophrenia. The AM-831 program has reached Phase I development. We intend to co-develop this compound in collaboration with Meiji Seika Pharma through completion of proof-of-concept clinical studies, at which point Meiji Seika Pharma will be solely responsible for continued development in the licensed Asian territory. Meiji Seika Pharma has exclusive rights to develop and commercialize AM-831 in Japan and several other Asian countries while ACADIA has retained rights to AM-831 in the rest of the world, including the United States and Europe.
back to top